A股異動 | 華熙生物(688363.HK)大漲超16% 獲多家券商集體唱好
格隆匯1月11日丨華熙生物(688363.HK)高開高走,現漲幅擴大至16.35%,報160.5元,總市值150億元。
1月7日國家衞健委發佈公吿,批准由華熙生物申報的透明質酸鈉(即透明質酸,HA)為新食品原料。為此公司獲多家券商集體唱好,海通證券指出,玻尿酸獲批食品原料,進一步打開公司成長空間。中信證券稱,公司食品級+化粧品級HA,產能約400+噸,產能儲備充足。未來有望新接食品級HA訂單,也或將推出含HA的功能性食品品牌。華泰證券維持公司買入,稱新規打開食品HA成長空間。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.